On the Sinclair front, I completely agree.
A second indication that targets a TAM that is multiples of what IIH is, now that's the true blue sky field.
Obviously we would need to do the waiting through phase I/II/III for it, but the market would love to see that occur and would see the phase III success of the IIH trial (if it were to occur) and rerate the likelihood of the early second indication success.
That is where the valuation would start spitting out some really interesting results.
Do you have an opinion on the drug pricing or market penetration figures? Even 30% of the market seems quite conservative given no other drug on the market for IIH
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5 | 9.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.21pm 14/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable